Skip to main content
SpringerLink
Log in

Botulinum Toxins

  • Chapter
Clinical Evaluation and Management of Spasticity

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

In recent years, there has been a dramatic increase in the use of botulinum toxin for the management of spasticity. Botulinum toxin is a unique compound, effective for a variety of conditions in which the predominant clinical feature is abnormal muscle contraction. Since 1989, a number of reports have demonstrated the usefulness of botulinum toxin injections to improve spasticity and reduce painful muscle spasms. Although use of botulinum toxin for spasticity is approved in many European countries, it is still considered “off-label” for use in spasticity in the United States.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Simpson, L. L. (1980) Kinetic studies on the interaction between botulinum toxin type A and the cholinergie neuromuscular junction. J. Pharmacol. Exp. Ther. 212, 16–21.

    CAS  PubMed  Google Scholar 

  2. Poewe, W., Schelosky, L., Kleedorfer, B., Heinen, E, Wagner, M., and Deuschl, G. (1992) Treatment of spasmodic torticollis with local injections of botulinum toxin. One year follow up in 37 patients. J. Neurol. 239, 21–25.

    Article  CAS  PubMed  Google Scholar 

  3. DasGupta, B. R. (1994) Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin, in Therapy with Botulinum Toxin ( Jankovic, J. and Hallett, M., eds.), Marcel Dekker, New York, pp. 15–39.

    Google Scholar 

  4. DasGupta, B. R. and Tepp, W. (1993) Protease activity of botulinum neurotoxin type E and its light chain: cleavage of actin. Biochem. Biophys. Res. Commun. 190, 470–474.

    Article  CAS  Google Scholar 

  5. Brin, M. F. (1997) Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 20 (Suppl. 6), S146 - S168.

    Article  Google Scholar 

  6. Coffield, J. A., Considine, R. V., and Simpson, L. L. (1994) The site and mechanism of action of botulinum neurotoxin, in Therapy with Botulinum Toxin ( Jankovic, J. and Hallet, M., eds.), Marcel Dekker, New York, pp. 3–13.

    Google Scholar 

  7. Simpson, L. L. (1989) Peripheral actions of the botulinum toxins, in Botulinum Neurotoxin and Tetanus Toxin ( Simpson, L. L., ed.), Academic Press, New York, pp. 153–178.

    Chapter  Google Scholar 

  8. Borodic, G., Johnson, E., Goodnough, M., and Schantz, E. (1996) Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46, 26–29.

    Article  CAS  PubMed  Google Scholar 

  9. Alderson, K., Holds, J. B., and Anderson, R. L. (1991) Botulinum induced alteration of nerve muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 41, 1800–1805.

    Article  CAS  PubMed  Google Scholar 

  10. Borodic, G. E., Ferrante, R., Pearce, L. B., and Smith, K. (1994) Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov. Disord. 9, 31–39.

    Article  CAS  PubMed  Google Scholar 

  11. Greene, P., Fahn, S., and Diamond, B. (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov. Disord. 9, 213–217.

    Article  CAS  PubMed  Google Scholar 

  12. Greene, P. E. and Fahn, S. (1996) Response to botulinum toxin F in seronegative botulinum toxin A resistant patients. Mov. Disord. 11, 181–184.

    Article  CAS  PubMed  Google Scholar 

  13. Janovic, J. and Schwartz, K. (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45, 1743–1746.

    Article  Google Scholar 

  14. Hatheway, C. H., Snyder, J. D., Seals, J. E., Edell, T. A., and Lewis, G. E. (1984) Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J. Infect. Dis. 150, 407–412.

    Article  CAS  Google Scholar 

  15. Doellgast, G. J., Beard, G. A., Bottoms, J. D., Mheng, T., Roh, B. H., Roman, M. G., et al. (1994) Enzyme-linked immunosorbent assay and enzyme-linkedcoagulation assay for detection of Clostridium botulinum neurotoxin A, neuro-toxin B, and neurotoxin E and solution phase complexes with dual label antibodies. J. Clin. Microbiol. 32, 105–111.

    CAS  Google Scholar 

  16. Hanna, P. A. and Jankovic, J. (1998) Mouse bioassay versus western blot assay for botulinum toxin antibodies-correlation with clinical response. Neurology 50, 1624–1629.

    Article  CAS  PubMed  Google Scholar 

  17. Brin, M. F., Lew, M. F., and Adler, C. H. (1999) Safety and efficacy of Neurobloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53, 1431–1438.

    Article  CAS  PubMed  Google Scholar 

  18. Brashear, A., Lew, M. F., Dykstra, D. D., Cornelia, C. L., Factor, S. A., and Rodnitzky, R. L. (1999) Safety and efficacy of Neurobloc (botulinum toxin type B) in type A responsive cervical dystonia. Neurology 53, 1439–1446.

    Article  CAS  PubMed  Google Scholar 

  19. Comella, C. L., Buchman, A. S., Tanner, C. M., Brown-Toms, N. C., and Goetz, C. G. (1992) Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 42, 878–882.

    Article  CAS  PubMed  Google Scholar 

  20. Geenen, C., Consky, E., and Ashby, P. (1996) Localizing muscles for botulinum toxin treatment of focal hand dystonia. Can. J. Neurol. Sci. 23, 194–197.

    CAS  PubMed  Google Scholar 

  21. Brin, M. F. and the Spasticity Study Group. (1997) Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Muscle Nerve 20 (Suppl. 6), S208 - S220.

    Google Scholar 

  22. Benecke, R. (1994) Botulinum toxin for spasms and spasticity in the lower extremities, in Therapy with Botulinum Toxin ( Jankovic, J. and Hallett, M., eds.), Marcel Dekker, New York, pp. 557–565.

    Google Scholar 

  23. Borg-Stein, J., Pine, Z. M., Miller, J. R., and Brin, M. F. (1993) Botulinum toxin for the treatment of spasticity in multiple sclerosis: new observation. Am. J. Phys. Med. Rehabil. 72, 364–368.

    Article  CAS  PubMed  Google Scholar 

  24. Snow, B. J., Tsui, J. K. C., Bhatt, M. H., Varelas, M., Hashimoto, S. A., and Caine, D. B. (1990) Treatment of spasticity with botulinum toxin: a double blind study. Ann. Neurol. 28, 512–515.

    Article  CAS  PubMed  Google Scholar 

  25. Dykstra, D. D. and Sidi, A. A. (1990) Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch. Phys. Med. Rehabil. 71, 24–26.

    CAS  PubMed  Google Scholar 

  26. Bohlega, S., Chaud, P., and Jacob, P. C. (1995) Botulinum toxin A in the treatment of lower limb spasticity in hereditary spastic paraplegia. Mov. Disord. 10, 399 (Abstract).

    Article  Google Scholar 

  27. Takanega, S., Kawahigashi, Y., Sonoda, Y., Horikiri, T., Hirata, K., Arimura, K., and Osame, M. (1995) Treatment of spastic paraparesis with botulinum toxin with reference to beneficial effects, disease severity and long-term treatment. Rinsho Shinkeigaku 35, 251–255.

    Google Scholar 

  28. Koman, L. A., Mooney, J. F., Smith, B., Goodman, A., and Mulvaney, T. (1993) Management of cerbral palsy with botulinum -A toxin: preliminary investigation. J. Pediatr. Orthop. 13, 489–495

    Article  CAS  PubMed  Google Scholar 

  29. Cosgrove, A. P. and Graham, H. K. (1992) Botulinum toxin A in the management of spasticity with cerebral palsy. Br. J. Surg. 74, 135–136.

    Google Scholar 

  30. Chutorian, A. and Root, L. (1994) Management of spasticity in children with botulinum A toxin. Intl. Pediatr. 9, 35–43.

    Google Scholar 

  31. Chutorian, A., Root, L., and BTA Study Group. (1995) A multicentered, randomized, double-blind placebo-controlled trial of botulinum toxin type A in the treatment of lower limb spasticity in pediatric cerebral palsy. Mov. Disord. 10, 364 (Abstract).

    Google Scholar 

  32. Corry, I. S. (1997) Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev. Med. Child. Neurol. 39, 185–193.

    Article  CAS  PubMed  Google Scholar 

  33. Das, T. K. and Park, D. M. (1989) Effect of treatment with botulinum toxin on spasticity. Postgrad. Med. J. pp. 208–210.

    Google Scholar 

  34. Memin, B., Pollack, P., Hommel, M., and Perret, J. (1992) Effects of botulinum toxin on spasticity. Rev. Neurol. 148, 212–214.

    CAS  PubMed  Google Scholar 

  35. Grazko, M. A., Polo, K. B., and Jabbari, B. (1995) Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 45, 712–717.

    Article  CAS  PubMed  Google Scholar 

  36. Dengler, R., Neyer, U., Wohlfarth, K., Bettig, U., and Janzik, H. H. (1992) Local botulinum toxin in the treatment of spastic drop foot. J, Neurol. 239, 375–378.

    CAS  Google Scholar 

  37. Jabbari, B., Polo, K. B., Ford, G., and Grazko, M. A. (1995) Effectiveness of botulinum toxin A in patients with spasticity. Mov. Disord. 10, 379 (Abstract).

    Google Scholar 

  38. Simpson, D. M., Alexander, M. D., O’Brien, C. F., Tagliati, M., Aswad, A., Leon, J. M., et al. (1996) Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial. Neurology 46, 1306–1310.

    Article  CAS  PubMed  Google Scholar 

  39. Yablon, S. A., Agana, B. T., Ivanhoe, C. B., and Boake, C. (1996) Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology 47, 939–944.

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. Lauren C. Seeberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher F. O’Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Springfield Clinic Neuroscience Institute, Springfield, IL, USA

    David A. Gelber MD

  2. Department of Neurology, Wake Forest University School of Medicine, Winston-Salem, NC, USA

    Douglas R. Jeffery MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Seeberger, L.C., O’Brien, C.F. (2002). Botulinum Toxins. In: Gelber, D.A., Jeffery, D.R. (eds) Clinical Evaluation and Management of Spasticity. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-092-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-092-6_13

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-109-7

  • Online ISBN: 978-1-59259-092-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation